SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice

There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low- and middle-income countries. Here, we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast (Pichia pastoris), as a suitable vaccine candidate agains...

Description complète

Détails bibliographiques

Auteurs principaux:	Jeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, Brian Keegan, Bin Zhan, Junfei Wei, Zhuyun Liu, Jungsoon Lee, Rahki Kundu, Rakesh Adhikari, Cristina Poveda, Maria Jose Villar, Ana Carolina de Araujo Leao, Joanne Altieri Rivera, Zoha Momin, Portia M. Gillespie, Jason T. Kimata, Ulrich Strych, Peter J. Hotez, Maria Elena Bottazzi
Format:	Artigo
Langue:	Inglês
Publié:	Taylor & Francis Group 2021-08-01
Collection:	Human Vaccines & Immunotherapeutics
Sujets:	covid-19 rbd alum pseudovirus coronavirus ace-2
Accès en ligne:	http://dx.doi.org/10.1080/21645515.2021.1901545
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!